# Y-mAbs Therapeutics
 (stock symbol: YMAB) Logo in transparent PNG and SVG formats

## Y-mAbs Therapeutics
 Logo large

### Y-mAbs Therapeutics
 Logo large Download PNG (34.83 KB)

![Y-mAbs Therapeutics
 Logo large Download PNG (34.83 KB)](/img/orig/YMAB_BIG-c25a01bb.png)

### Y-mAbs Therapeutics
 Logo large Download SVG (25.54 KB)

![Y-mAbs Therapeutics
 Logo large Download SVG (25.54 KB)](/img/orig/YMAB_BIG-eeec42c7.svg)

## Y-mAbs Therapeutics
 Logo icon format

### Y-mAbs Therapeutics
 Logo icon format Download PNG (76.2 KB)

![Y-mAbs Therapeutics
 Logo icon format Download PNG (76.2 KB)](/img/orig/YMAB-a3c219da.png)

### Y-mAbs Therapeutics
 Logo icon format Download SVG (3.14 KB)

![Y-mAbs Therapeutics
 Logo icon format Download SVG (3.14 KB)](/img/orig/YMAB-f4f22554.svg)

## Y-mAbs Therapeutics
 Logo large for dark backgrounds

### Y-mAbs Therapeutics
 Logo large for dark backgrounds Download PNG (20.94 KB)

![Y-mAbs Therapeutics
 Logo large for dark backgrounds Download PNG (20.94 KB)](/img/orig/YMAB_BIG.D-c31a2999.png)

### Y-mAbs Therapeutics
 Logo large for dark backgrounds Download SVG (25.44 KB)

![Y-mAbs Therapeutics
 Logo large for dark backgrounds Download SVG (25.44 KB)](/img/orig/YMAB_BIG.D-d7fba844.svg)

## Y-mAbs Therapeutics
 Logo icon format for dark backgrounds

### Y-mAbs Therapeutics
 Logo icon format for dark backgrounds Download PNG (41.45 KB)

![Y-mAbs Therapeutics
 Logo icon format for dark backgrounds Download PNG (41.45 KB)](/img/orig/YMAB.D-0c58d100.png)

### Y-mAbs Therapeutics
 Logo icon format for dark backgrounds Download SVG (3.07 KB)

![Y-mAbs Therapeutics
 Logo icon format for dark backgrounds Download SVG (3.07 KB)](/img/orig/YMAB.D-4787c4f2.svg)

## About Y-mAbs Therapeutics


Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

1. Website domain: ymabs.com
2. Employees: 148
3. Marketcap: $0.26 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
